Muscle Loss on GLP-1s in Menopause: Why the Risk Doubles

GLP-1 medications are typically evaluated, marketed, and celebrated by one number: total weight lost, or the percentage drop on the scale. That number doesn't distinguish between fat and muscle, and for most of the public conversation around these drugs, it hasn't needed to — the headline results are genuinely impressive. But weight loss is not automatically fat loss. When the body is in a significant calorie deficit, which is essentially what happens with reduced appetite on a GLP-1, it breaks down some muscle tissue for energy alongside fat, especially without deliberate effort to prevent it through resistance exercise and adequate protein. This isn't unique to GLP-1s — it happens with any substantial, sustained weight loss, including bariatric surgery and aggressive dieting. What's different is the scale at which GLP-1s are now being used, and for how long, which has pushed researchers to look more closely at body composition specifically, not just the number on the scale.

A body-composition substudy of STEP 1 (Wilding et al., published as a companion analysis in Diabetes, Obesity and Metabolism) used DXA scans — the gold-standard imaging method for measuring fat versus lean tissue — and found that of the total weight lost on semaglutide, a meaningful portion, commonly cited in the range of 25-40% depending on the specific analysis and population, was lean mass rather than fat mass. A similar body-composition substudy of SURMOUNT-1 with tirzepatide found broadly comparable proportions. For context, this proportion isn't dramatically different from what's seen with calorie restriction alone in older adults — the issue isn't that GLP-1s are uniquely harmful to muscle, but that the sheer magnitude of weight loss (often 15-20%+ of body weight) means the absolute amount of lean mass lost can be substantial even if the percentage split looks similar to other weight-loss methods. Losing several pounds of muscle matters more for a 55-year-old woman who is already in a phase of natural muscle decline than for a 30-year-old with more baseline reserve.

Muscle loss with age — sarcopenia — happens to everyone eventually, but it isn't a steady, linear process for women; it accelerates measurably around the menopause transition. Research from the SWAN cohort tracking body composition through midlife (Greendale et al., JCI Insight, 2019) found that the rate of lean mass loss increased notably in the years immediately around the final menstrual period, coinciding with the sharpest drop in estrogen, and this pattern was distinct from ordinary aging-related decline seen before that window. Estrogen appears to support muscle protein synthesis and may have a protective effect on muscle tissue directly, separate from its more widely discussed roles in bone and cardiovascular health. This means a woman starting a GLP-1 during or after menopause is contending with two simultaneous pressures on lean mass: the medication-associated loss documented in trial substudies, and the menopause-associated acceleration in muscle decline that would be happening with or without the medication. Neither factor alone is necessarily alarming — but together, without a deliberate counter-strategy, they compound.

General sports nutrition and geriatric research both point toward a similar target for anyone actively trying to preserve muscle during weight loss: roughly 1.2-1.6 grams of protein per kilogram of body weight per day (about 0.55-0.73g per pound), notably higher than the general population RDA of 0.8g/kg, which was designed to prevent deficiency, not to support muscle retention during active weight loss. On a GLP-1, hitting that target is genuinely harder than it sounds, because reduced appetite makes eating enough of anything a challenge — which is why protein-forward, lower-volume foods (Greek yogurt, cottage cheese, eggs, lean meats, protein shakes when appetite is very low) tend to work better than trying to eat large meals. Resistance training — using weights, resistance bands, or bodyweight exercises against muscle — is the other essential piece, and arguably the more important one; multiple studies on weight loss interventions have found that adding resistance training meaningfully reduces the proportion of weight lost as muscle compared to calorie restriction or medication alone, even without changing total weight loss. Two to three sessions a week targeting major muscle groups is a reasonable starting target for most people, adjusted for current fitness level and any other health considerations.

The scale alone can't tell you, which is exactly the problem this article is describing. A DXA scan (dual-energy X-ray absorptiometry) is the most precise widely available tool — many people already get one for bone density and can request the body-composition breakdown from the same scan, since it measures fat, lean mass, and bone in one pass. Bioelectrical impedance scales (including many smart scales) are a rougher, more accessible alternative, though accuracy varies significantly based on hydration status and the specific device — useful for tracking general trends over time rather than precise numbers. [Grip strength](/blog/grip-strength-in-menopause-why-it-matters) is a simple, low-cost functional proxy that correlates with overall muscle health and is increasingly used in research as a marker worth tracking on its own. Practically, warning signs worth paying attention to include feeling notably weaker in daily tasks (carrying groceries, climbing stairs) even as the scale number drops, unusual and persistent [fatigue](/blog/glp1-fatigue-in-menopause-why-youre-so-tired), or visible loss of muscle definition alongside looser skin — a pattern sometimes discussed alongside [GLP-1-related skin changes](/blog/glp1-and-menopausal-skin-changes-collagen-sagging-what-helps), since collagen and underlying tissue loss can compound visually. If you're noticing plateaus alongside these signs, it's also worth reading about [GLP-1 dose creep](/blog/glp1-dose-creep-why-higher-doses-stop-working-as-well), since chasing the scale number with dose increases, without addressing body composition, can worsen the muscle-to-fat ratio of what you're losing rather than improving it.